APMD

Apnimed, Inc. Common Stock

15.10

USD

+0.94

+6.64%

Nov 06, 15:59 UTC -5

Closed

After-Market

15.10

0.00

-0.03%

Apnimed, Inc. Common Stock (APMD) Earnings

APMD Earnings Reports

Positive Surprise Ratio

APMD beat 1 of 1 last estimates.

100%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Apnimed, Inc. Common Stock earnings per share and revenue

On Sep 08, 2026, APMD reported earnings of -0.34 USD per share (EPS) for Q2 26, beating the estimate of -0.52 USD, resulting in a 34.64% surprise. Revenue reached 12.08 million, compared to an expected --, with a 0.00% difference. The market reacted with a -2.47% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Xeris Biopharma Holdings, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.02

Actual

$0.06

Surprise

+144.90%

Cronos Group Inc. Common Share

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.03

Actual

$0.04

Surprise

+17.65%

Collegium Pharmaceutical, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.89

Actual

$1.96

Surprise

+3.17%

Ironwood Pharmaceuticals, Inc. - Class A

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.32

Actual

$0.36

Surprise

+9.16%

ARS Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.32

Actual

-$0.36

Surprise

-11.15%

Profound Medical Corp. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.18

Actual

-$0.21

Surprise

-11.41%

Akebia Therapeutics, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.03

Actual

-$0.04

Surprise

-6.95%

Organogenesis Holdings Inc. Class A Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.17

Actual

-$0.25

Surprise

-40.06%

ZOETIS INC.

Report Date

Nov 05, 2026 For Q3 26

Estimate

$1.52

Actual

$1.75

Surprise

+14.64%

Amylyx Pharmaceuticals, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.38

Actual

-$0.38

Surprise

+1.04%

FAQ

What were Apnimed, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Apnimed, Inc. Common Stock reported EPS of -$0.34, beating estimates by 34.64%, and revenue of $12.08M, 0% as expectations.

How did the market react to Apnimed, Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -2.47%, changed from $28.79 before the earnings release to $28.08 the day after.

When is Apnimed, Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Apnimed, Inc. Common Stock's next earnings report?

Based on -- analysts, Apnimed, Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.